Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp twice daily versus IDegAsp once daily plus insulin aspart twice daily in type 2 diabetes
ChiCTR2200060640Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin degludec + insulin aspart and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Change from baseline in HbA1c. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
insulin degludec + insulin aspartinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200060640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060640.